By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TRANSGENE S.A. 

11 rue de MOLSHEIM, 67082
Strasbourg
Cedex      France
Phone: 011-33-3-88-27-91-21 Fax: 011-33-3-88-27-91-11


SEARCH JOBS


Industry
Biotechnology

Segment
Gene Therapy

Collaborations

Human Genome Sciences, Inc.  Gene Therapy Partnerships





Company News
Marie Landel And Maya Said Nominated To Be Independent Members Of TRANSGENE (ENX:TNG)’s Board Of Directors 4/19/2017 12:04:15 PM
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017 11:10:22 AM
TRANSGENE (ENX:TNG) Presents Very Promising New Immunology Data Of Its Next Generation Armed Oncolytic Virus At The AACR Annual Meeting In Washington, DC 3/31/2017 7:25:41 AM
TRANSGENE (ENX:TNG) Presents Very Promising New Immunology Data Of Its Next Generation Armed Oncolytic Virus At The AACR Annual Meeting In Washington, DC 3/30/2017 12:55:53 PM
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017 10:25:13 AM
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017 11:04:49 AM
TRANSGENE (ENX:TNG) And Léon Bérard Cancer Center Announce Dosing Of The First Patient In A Phase 1 Immunotherapy Clinical Trial Evaluating The Intra-Tumoral Co-Administration Of Pexa-Vec Plus Ipilimumab (Yervoy) In Solid Cancers 2/13/2017 10:27:07 AM
TRANSGENE (ENX:TNG) Announces Financial Calendar for 2017 1/5/2017 11:28:52 AM
Elsalys Biotech Acquires Rights Of TRANSGENE (ENX:TNG)'s Anti-CD115 Antibody 12/16/2016 8:49:37 AM
TRANSGENE (ENX:TNG), UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016 11:27:42 AM
12345678910...
//-->